Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NANOS1 + colloidal silver is a combination product consisting of two components: - **NANOS1**: There is no evidence in the provided sources or in widely available scientific literature that "NANOS1" refers to an approved drug, supplement, or recognized active pharmaceutical ingredient. It may be a code name, research compound, or proprietary formulation not documented in major databases. - **Colloidal Silver**: Colloidal silver consists of tiny particles of elemental silver suspended in liquid. Historically used for its purported antimicrobial properties before the advent of antibiotics, it has been marketed as a dietary supplement and topical agent for wound healing. However, there is no clinical evidence supporting its effectiveness for any disease or condition when taken orally or applied topically[1][2][3]. The FDA does not recognize it as safe or effective for any medical use[6]. The mechanism of action attributed to colloidal silver involves disruption of microbial cell membranes and proteins via released Ag+ ions and induction of oxidative stress within pathogens[5][8]. Despite these laboratory findings, clinical efficacy remains unproven.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NANOS1 + colloidal silver.